Nevertheless, based on the established efficacy of SAM and anti-PD-1 antibody in several cancers, including melanoma, we anticipate continued benefit and effectiveness of SAM+anti-PD-1 in a luminal B BCa model, which could be translated to a clinical setting [28,30]. This evidence concerns the gene PDCD1 and cancer.